Daraxonrasib monotherapy in second-line PDAC showed a confirmed ORR of 35% with median overall survival exceeding 13 months. How do these outcomes compare to historical second-line benchmarks, and what do they suggest about durability

The safety findings were consistent across both 1L and 2L PDAC cohorts with no new signals. How important is this consistency when considering daraxonrasib’s transition into earlier-line therapy?

In treatment-naïve patients, daraxonrasib monotherapy produced an ORR of 47% and DCR of 89%. What is the significance of these early findings, and what durability signals would you need to see in follow-up to confirm clinical value?

The daraxonrasib plus gemcitabine/nab-paclitaxel regimen delivered a 55% ORR with a 90% DCR. What advantages does the combination strategy offer over standard chemotherapy alone, and do you foresee it becoming competitive as a new first-line standard?

Daraxonrasib targets multiple KRAS G12X variants, including G12D and G12V, which are common in PDAC. How does this broad selectivity impact its potential reach compared to mutation-specific inhibitors?

With multiple KRAS inhibitors in development, how might daraxonrasib fit into treatment sequencing for RAS-mutant cancers, particularly in pancreatic cancer but also in NSCLC and CRC?

The Phase 3 RASolute 303 trial will compare daraxonrasib monotherapy and daraxonrasib plus chemotherapy against a GnP control arm. From a design standpoint, what key endpoints and patient selection criteria will be most critical for regulatory success?

Given PDAC’s historically poor prognosis, what would successful Phase 3 results mean not just for pancreatic cancer patients but for advancing the field of RAS-targeted oncology more broadly?